Patents by Inventor The University of Dundee

The University of Dundee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC APPLICATIONS OF P53 ISOFORMS IN REGENERATIVE MEDICINE, AGING AND CANCER
    Publication number: 20150299706
    Abstract: The present invention provides methods and compositions for modulating cell senescence and cell proliferation using isoforms of the p53 tumor suppressor protein. The methods and compositions of the invention find use in inhibiting cancer cell growth or in generating populations of cells for tissue regeneration through the modulation of cell senescence and proliferation.
    Type: Application
    Filed: June 29, 2015
    Publication date: October 22, 2015
    Inventors: The United States of America as Represented by the Secretary of the Department of Health and Human Services, The University of Dundee, Masaryk Memorial Cancer Institute
  • P53 ACTIVATING COMPOUNDS
    Publication number: 20130310382
    Abstract: The present invention relates to compounds which activate the p53 response, and find use in, for example, hyperproliferative diseases such as cancer treatment and potentially other diseases/conditions involving sirtuin function.
    Type: Application
    Filed: May 3, 2013
    Publication date: November 21, 2013
    Inventors: University Court of the University of Dundee, University Court of the University of St. Andrews
  • SELECTIVE GLYCOSIDASE INHIBITORS
    Publication number: 20130131102
    Abstract: The present invention provides glucoimidazole derivatives and methods of making them. The compounds can be used to inhibit the activity of O-GlcNAcase enzymes, including both bacterial OGA (bOGA) and human OGA (hOGA) and can be selective, showing low inhibition of hexosaminidases. The compounds can be used to study the role of the O-GlcNAcase modification in human or animal cells. Furthermore the compounds can have therapeutic uses in the treatment of diseases mediated by the activity of O-GlcNAcase enzymes including type II diabetes, Alzheimers Disease, and cancer.
    Type: Application
    Filed: November 13, 2012
    Publication date: May 23, 2013
    Applicant: The University Court of the University of Dundee
    Inventor: The University Court of the University of Dundee